Business Context and Reporting Period
Company: MICROVISION, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2000
Business Overview: Microvision develops and commercializes Retinal Scanning Display technology, which projects high-resolution images directly onto the viewer's retina. The company is in a pre-commercialization phase, focusing on R&D, prototype development, and securing development contracts with government and commercial entities. Key product targets include simulation, avionics, medical, and wearable systems.
Key Financial Metrics
| Metric | Q1 2000 | Q1 1999 |
|---|---|---|
| Contract Revenue | $2,109,500 | $2,301,600 |
| Gross Margin | $642,000 (30.4%) | $592,000 (25.7%) |
| Net Loss | $(5,073,200) | $(2,002,000) |
| Net Loss Per Share (Basic/Diluted) | $(0.48) | $(0.51) |
| Cash and Cash Equivalents | $3,730,200 | $2,798,000 |
| Total Liquid Assets (Cash + Investments) | $30,445,400 | $32,167,400 |
| Net Cash Used in Operating Activities | $(3,677,100) | $(2,515,000) |
| Total Debt (Current + Long-term) | $658,900 | $618,200 |
Material Changes vs. Prior Period
- Revenue Decline: Contract revenue decreased by approximately 8% ($200,000) due to lower revenue recognition from development contracts compared to the prior year.
- Expense Surge:
- R&D Expenses: Increased 308% to $3.6 million (from $0.9 million) driven by hiring technical staff, equipping in-house laboratories, and intellectual property maintenance.
- SG&A Expenses: Increased 45% to $2.5 million (from $1.7 million) due to higher compensation and support costs for sales and administrative staff.
- Interest Income: Increased 874% to $452,000, resulting from higher average balances in cash and investment securities.
- Cash Flow: Net cash used in operations increased to $3.7 million, primarily reflecting the widened net loss. However, investing activities provided $2.3 million due to the timing of investment security maturities.
Outlook, Risks, and Subsequent Events
Management Commentary & Guidance:
- The company expects to continue funding prototypes through 2000, with a production version of the Retinal Scanning Display targeted for introduction in 2001.
- Management anticipates continued high levels of R&D spending and increasing operating losses as the company scales operations.
- Liquidity is sufficient to meet budgeted requirements for at least the next 12 months based on the current operating plan.
Risks & Contingencies:
- Future success depends on market acceptance of the technology and the ability to secure OEM partnerships.
- There is no assurance that additional financing will be available on acceptable terms if required to accelerate development or respond to competition.
- Interest rate risk is considered immaterial as the portfolio consists of high-grade government agency securities and commercial paper.
Subsequent Events (Post-March 31, 2000):
- April 2000 Financing: Completed a sale of 500,000 shares of common stock to Cree, Inc. and General Electric Pension Trust for $25.0 million.
- Warrant Exercise: A private investor exercised a warrant for 418,848 shares at $17.91 per share, generating $7.5 million in proceeds.
Investor Verification Checklist
- Capital Runway: Verify the impact of the $32.5 million in subsequent financing (April 2000) on the company's liquidity and ability to fund operations beyond the 12-month horizon stated in the filing.
- R&D Efficiency: Monitor the ratio of R&D spend to revenue to assess the timeline for commercialization given the 308% increase in R&D expenses.
- Revenue Concentration: Review the nature of development contracts to determine reliance on government vs. commercial customers and the sustainability of contract revenue.
- Product Timeline: Validate the feasibility of the 2001 production launch date for the Retinal Scanning Display.
- Dilution: Assess the dilution impact from the recent issuance of 500,000 shares and the warrant exercise on existing shareholders.